Safety and efficacy study of oliceridine combined with propofol in painless gastroscopy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400092206

Enrollment

Unknown

Registered

2024-11-12

Start date

2024-11-20

Completion date

Unknown

Last updated

2024-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless gastroscopy patients

Interventions

group S:sufentanil + propofol

group O:oliceridine + propofol

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: ?Those who undergo painless gastroenteroscopy; ?Aged 18-60 years old; ?With ASA classification of grade ?-?; ?Be informed of this study and sign the consent form.

Exclusion criteria

Exclusion criteria: ?Upper gastrointestinal bleeding or abnormal coagulation function. ?Long-term use of opioids. ?Respiratory diseases such as respiratory tract infection, asthma, and sleep apnea syndrome. ?History of allergy to the drugs used in this anesthesia regimen. ?Pregnancy. ?Abnormal liver or kidney function. ?Confused and unable to cooperate with the researchers.

Design outcomes

Primary

Measure	Time frame
Respiratory-related adverse reactions;pain score;	—

Secondary

Measure	Time frame
Vital signs;MMSE;Occurrence of adverse reactions such as nausea and vomiting, choking and coughing;	—

Countries

China

Contacts

Public ContactLu Xihua

Affiliated Cancer Hospital of Zhengzhou University

hnlxh66@163.com+86 135 0386 6911

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026